Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2012 by Uppsala University Hospital
Sponsor:
Information provided by (Responsible Party):
Hans Mallmin, Uppsala University Hospital
ClinicalTrials.gov Identifier:
NCT01630941
First received: June 26, 2012
Last updated: June 27, 2012
Last verified: June 2012
  Purpose

The primary objective is to study the effect of Denosumab on Bone Mineral Density, Standardised Uptake Value and bone metabolism in patients with total hip arthroplasty. The primary hypothesis is to demonstrate that Denosumab is superior to placebo.


Condition Intervention Phase
Osteoarthritis, Hip
Ambulation Difficulty
Drug: denosumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Uncemented Total Hip Implant and Subcutaneous Injections of Denosumab for Patients With Osteoarthritis of the Hip. A Randomized Double Blind Placebo Controlled Study on the Effects on Bone Evaluated With DXA, PET/CT and Biochemical Markers

Resource links provided by NLM:


Further study details as provided by Uppsala University Hospital:

Primary Outcome Measures:
  • Bone Mineral Density [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Bone mineral density by DXA in Gruen Zone 7 and a sum of Gruen zone 1-7


Secondary Outcome Measures:
  • Bone mineral Density [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    BMD, g/cm2, adjacent to the femur implant for Gruen Zone 1-7, 3, 6, and 24 months after surgery

  • Standardised Uptake value [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    fluoride isotope uptake, measured as (SUV), adjacent to the femoral stem, 3 and 6 months after surgery.

  • Standardised Uptake value [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    fluoride isotope uptake, measured as SUV adjacent to the acetabular cup 3 and 6 months after surgery

  • Bone Mineral density [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    BMD adjacent to the acetabular cup during the follow up period, i.e. after 3, 6, 12 and 24 months

  • Bone Mineral Density [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    BMD at the lumbar spine and at the contra lateral nonoperated hip 6, 12 and 24 months after surgery

  • Standardised Uptake Value [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Fluoride isotope uptake measured as SUV at the lumbar spine and at the contra lateral nonoperated hip after 3 and 6 months

  • Biochemical markers for bone metabolism [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    biochemical markers for bone turnover and the relation to SUV and BMD findings at the proximal femur and acetabulum during the follow up period, i.e. 3, 6, 12 and 24 months after surgery

  • Biochemical markers for bone metabolism in relation to Bone Mineral Density and Standardised Uptake Value [ Time Frame: 24 ] [ Designated as safety issue: No ]
    biochemical markers for bone turnover and the relation to SUV and BMD findings at anatomical sites not exposed to surgery, i.e. the lumbar spine and the contra lateral hip 3 and 6 months after surgery

  • Biochemical markers for bone metabolism in relation to Bone Mineral Density and Standardised Uptake Value [ Time Frame: 24 ] [ Designated as safety issue: No ]
    to evaluate the natural course of an uncemented THA on BMD, i.e. the placebo group 3, 6, 12 and 24 months after surgery, SUV i.e. the placebo group 3 and 6 months after surgery and on biochemical markers, i.e. the placebo group 3, 6, 12 and 24 months after surgery

  • Clinical outcome evaluation [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    to evaluate the patients Quality of Life, measured by Harris Hip score and EQ-5D questionnaires

  • Adverse events [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    incidence and severity of adverse events (AEs) during the study period


Estimated Enrollment: 64
Study Start Date: March 2012
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Denosumab
1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
Drug: denosumab
Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
Other Name: Prolia
Placebo Comparator: saline
1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later
Drug: denosumab
Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
Other Name: Prolia

Detailed Description:

A clinical study with 64 patients, age 35-65 years, with unilateral osteoarthritis of the hip, randomised to two groups of patients, either receiving Denosumab or placebo

The patients will operated with an uncemented total hip arthroplasty with a Continuum acetabular cup with trabecular surface (Tantalum) and longevity Highly Cross-linked Polyethylene liner, Zimmer, Warsaw, IN, USA, and a CFP femoral stem with Titanium surface and a chrome cobalt 28 mm head, Waldemar Link, Hamburg, Germany.

Clinical outcome evaluated by Harris Hip Score and EQ-5D, Bone Mineral Density by DXA, Standardised Uptake Value of Fluoride tracer, by PET/CT and biochemical markers for bone formation and bone resorption will be analyzed together with conventional radiology for implant position and fixation.

  Eligibility

Ages Eligible for Study:   35 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. male or female patient 35-65 years of age with an unilateral OAH requiring a THA and a healthy contralateral hip
  2. body weight ≤110 kg or body mass index (BMI) ≤35 kg/m2
  3. living in the Uppsala County
  4. the eligible patients should have been given oral information, a written Patient Information and signed an Informed Consent

Exclusion Criteria:

  1. on or previously have had bone-specific treatment, e.g. bisphosphonates, raloxifene, parathyroid hormone, strontium ranelate, during the last five years
  2. patients on systemical corticosteroid for more than 3 months should not be considered
  3. patients with diagnosed malignant disease during the last five years or known to have metastasis from malignant disease should be excluded
  4. patients with compromised general conditions and an American Society of Anesthesiologists, ASA-score >31 should not be regarded eligible
  5. patients with known drug or alcohol abuse or regarded as socially dysfunctional, as judged by the investigator, should not be considered for the study
  6. pregnant women or women planning for pregnancy or fertile women (premenopausal) without contraceptives should not be accepted for the study
  7. patients that have been exposed frequently and/or have had large irradiation doses, as judged by the investigator, must not be included in the study.
  8. enrolled in either another investigational drug study, in another investigational device study, or in another investigational study of an approved drug within 30 days prior to Visit 1 of the current study
  9. any condition or laboratory findings which in the opinion of the Investigator makes the patient unsuitable for inclusion (for example claustrophobia)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01630941

Contacts
Contact: Hans Mallmin, MD PhD +46186114478 hans.mallmin@akademiska.se
Contact: Nils Hailer, MD, PhD +46186119038 nils.hailer@akademiska.se

Locations
Sweden
Department of Orthopedics Recruiting
Uppsala, Sweden
Contact: Catharina Stromstedt       catharina.stromstedt@akademiska.se   
Principal Investigator: Hans Mallmin, MD, PhD         
Sub-Investigator: Nils Hailer, MD, PhD         
Sub-Investigator: Jan Milbrink, MD, PhD         
Sub-Investigator: Demostenis Kiritopoulos, MD         
Sub-Investigator: Andreas Nystrom, MD         
Sponsors and Collaborators
Hans Mallmin
Investigators
Principal Investigator: Hans Mallmin, MD, PhD Uppsala University
Study Chair: Nils Hailer, MD, PhD Uppsala University
  More Information

No publications provided

Responsible Party: Hans Mallmin, MD, PhD, Uppsala University Hospital
ClinicalTrials.gov Identifier: NCT01630941     History of Changes
Other Study ID Numbers: 2011-001481-18
Study First Received: June 26, 2012
Last Updated: June 27, 2012
Health Authority: Sweden: Swedish National Council on Medical Ethics

Keywords provided by Uppsala University Hospital:
Osteoarthritis of the hip
Uncemented Total Hip Arthroplasty
DXA
BMD
PET
CT
Biochemical bone markers

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Hip
Mobility Limitation
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on July 31, 2014